§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
EP0074279A2 Expired / Lapsed EP ⏱️ 0.0 years remaining

Selective anti-tumour agents

Assignee: Suntory Ltd
•
Filing: 1982-09-08
•
Granted: —
•
Expires: 2002-09-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A selective anti-tumour agent comprises a carrier portion and a voluntary anti-tumour active agent. The carrier portion is a monoclonal antibody (MoAb) which is produced by a hybridoma formed by cell fusion between two kinds of animal cells, one of which is an animal cell sensitized by human tumour cell such as spleen cell of BALB/ c mouse and another of which is another animal cell such as mouse myeloma cell. The antibody is isolated from the hybridoma and chemically conjugated with a voluntary anti-tumour ingredient such as an alkylating agent, anti-metabolic agent, cytotoxic antibiotic, protein or polypeptide, toxin or alkaloid. The resultant thermapeutic MoAb conjugate selectively binds with specific tumour cells or tissue having a corresponding antigen and selectively attacks said cells or tissue as its target.

Inventors

  • 👤 Toshihiro Nakanishi
  • 👤 Hajime Yoshizumi
  • 👤 Kozo Imai
  • 👤 Akira Yachi
  • 👤 Ferrone Soldano

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-11-06 13:42
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3053; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6851; A61K47/6865; A61P; A61P35/00; A61K38/00

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 30 words
A selective anti-tumour agent comprising an anti-tumour active substance chemically conjugated with an antibody as a carrier characterised in that the antibody is a monoclonal antibody to the tumour antigen.
Claim 2
Dependent Claim 30 words
A selective anti-tumour agent comprising an anti-tumour active substance chemically conjugated with an antibody as a carrier characterised in that the antibody is a monoclonal antibody to the tumour antigen.
Claim 3
Dependent Claim 15 words
An agent as claimed in claim 1, wherein the monoclonal antibody is produced by hybridoma.
Claim 4
Dependent Claim 32 words
An agent according to claim 1, wherein the hybridoma is a fused cell formed by cell fusion between an animal cell sensitized by a human tumour cell and an animal myeloma cell.
Claim 5
Dependent Claim 14 words
An agent according to claim 3, wherein said animal cell is a spleen cell.
Claim 6
Dependent Claim 18 words
An agent according to claim 3 or 4, wherein said human tumour cell is a malignant melanoma cell.
Claim 7
Dependent Claim 22 words
An agent according to any preceding claim, wherein the anti-tumour active substance is a cytotoxic basic polypeptide derived from barley or wheat.
Claim 8
Dependent Claim 36 words
An agent according to any preceding claim, wherein free carboxyl radicals of acidic amino acid groups in the antibody and amino radicals of ε-lysine in the anti-tumour active substance are combined to form acid amide groups.
Claim 9
Dependent Claim 39 words
An agent according to any one of claims 1 to 6, wherein free amino radicals of basic amino acid groups in the antibody and free carboxyl radicals in the anti-tumour active substance are combined to form acid amide groups.
Claim 10
Dependent Claim 43 words
An agent according to any one of claims 1 to 6, wherein free amino radicals of basic amino acid groups in the antibody and nuclear carbon atoms in the anti-tumour active substance containing sugar as a constituent are combined to form aminomethyl groups.
Claim 11
Dependent Claim 37 words
An agent according to any one of claims 1 to 6, wherein free amino radicals of basic amino acids in the antibody are cross-linked with amino radicals in the anti-tumour active substance by a saturated divalent aldehyde.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag